Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 3/20 | 0.44 |
| ▸ | MALT1 | Q9UDY8 | 11/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6082306 | 0.99 | SLC9A1 (0.44) | SLC9A1MALT1MEN1KMT2AHTR2C | |
| SCHEMBL6081888 | 0.92 | MALT1 (0.41) | SLC9A1MALT1KMT2AHTR2CALDH1A1 | |
| SCHEMBL15072233 | 0.82 | MALT1 (0.41) | MALT1MEN1KMT2AHTR2CALDH1A1 | |
| SCHEMBL6312790 | 0.82 | SLC9A1 (0.44) | SLC9A1MALT1MEN1KMT2AHTR2C | |
| SCHEMBL6083025 | 0.81 | SLC9A1 (0.46) | SLC9A1MALT1MEN1KMT2AHTR2C | |
| SCHEMBL6082715 | 0.81 | RET (0.36) | MALT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6082885 | 0.81 | TLR8 (0.37) | MALT1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6312192 | 0.81 | SLC9A1 (0.43) | SLC9A1MALT1MEN1KMT2AHTR2C | |
| SCHEMBL6082191 | 0.81 | BTK (0.36) | MALT1HTR2C | |
| SCHEMBL6082925 | 0.81 | KDM4E (0.46) | SLC9A1MALT1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078414-B2 | Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-18 | — | — | US | claimed |
| US-20040266775-A1 | Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-30 | — | — | US | claimed |
| US-7078414-B2 | Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-18 | — | — | US | disclosed |
| US-20040266775-A1 | Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-30 | — | — | US | disclosed |
| WO-2004007478-A2 | DERIVATIVES OF 3-GUANIDINOCARBONYL-1-HETEROARYL-PYRROLE, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266775-A1 | Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | GPBAR1, ADRB3, ADRA1A | SLC9A1 4412/4885MALT1 1215/4885MEN1 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.